NEW YORK, Oct. 3 - Quark Biotech said Wednesday that it would use its gene and protein function profiling technology to supply AstraZeneca with potential cancer targets.

Under the terms of the deal, Quark, a Cleveland-based company that conducts most of its research in Israel, will provide AstraZeneca of London with 100 genes and proteins it identifies using its platform, known as BiFAR. The companies will also work together to evaluate and validate the function of these potential targets.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A fire at a Manchester hospital may have destroyed lab equipment and data, the Guardian reports.

Researchers generate a genetic database from skeletal remains from the 1845 Franklin Expedition to the Arctic, Live Science reports.

Researchers in China have begun another trial using CRISPR/Cas9 approaches in cancer patients, according to the Wall Street Journal.

In Science this week: human DNA found in sediments from archeological sites lacking bones, and more.